Breast Cancer and Hormones
- ACS Key Statistics for Breast Cancer
- Adams 98 Adrenal andro low BC BCRT
- Aiello 05 Br Density mam hormones inverse CEB&P
- Abstract TE inhibits Aromatase BCA cells HMBCI.pdf
- Akahori 08 RBA ER A TiV
- Anderson 82 mitosis apoptosis Br cell Prog age BJC
- Anderson 97 PCO No increase B Ca Cancer
- Ando 02 Br Ca Estrogen Androgen Receptor MCE
- Antiestrogen action of Prog Mauvais-Jarvis BCRT 86
- Antoine 06 HRT (ERT) after BCa HR
- Androgens and Mammary Ca Fer Ster 02
- AR gene difficult 02
- AR mutation Male BCa
- Aromatase BC Cells 99
- Aromatase Inhi NEJM 03 HRT & AI
- Baber 05 Review Rx men,HRT BCa Drug Safety
- Badwe 91 Timing Surg BCa Survival Lancet
- Barclay 06 Pregnacy in BCa survivors BMJ
- Barrett-Connor 01 HRT Risk Benefits IJE
- Barrett-Connor 06 Raloxifene CV BrCa NEJM
- Basly 05 Phytoestrogens SERM Planta Med
- BC HRT Lancet 97
- BC HRT Lancet 97 commentary
- BCDDP Br C HRT JAMA 00
- Bcl-2,p53 BC inhibition Progesterone Formby 98 M&CB
- Beral 11 MWS incidence BCa ert NCI
- Bergink 84 Estriol vs E2 binding proteins affinity JSB
- Bergkvist 89 Risk Br Ca HRT estriol E2 Prem NEJM
- Berrino 05 Serum test BCa recurrence Int J Ca
- Biche 01 AR BRCA breast tumors C
- Biglia 08 OCP Increase BCa BRCA Mat
- Biology of Breast Cancer
- Birrell 07 AR Progestin BCa Abstract
- Birrell 07 Progestins AR BCa FASEB
- Birrell 98 AR in BC JMGBN
- Bitzer 08 Testosterone HRT Maturitas
- BJOG 05 Review HRT
- Blair 00 RBA estrogens Tox
- Bluming 04 HRT in BCa pts. JCO
- Boccuzzi 94 Adr androgens inhibits BCa BJCa
- Bone doseBC risk BMJ 98
- Bonnier 95 HRT Px.BCa OG
- Boyd 02 Mam density endo hormone BJC
- Br Ca hormone profile 2005 Ca Epi Bio
- Br Ca risk (DCIS) no asso risk hormone levels 2004 I J Ca
- BRCA 1 AR signaling 99
- Breast Ca Risk Catechol Estro InJCa 05
- Brinton 07 Hormones BCa edi CEBP
- Brodie Macedo Androgen with AI CR
- Buchanan 05 AR BCa inhib CR
- Chang, K 95 Percut E2 P Breast cell FS
- Bundred ERT Tibil after BCa Mat
- Burger 06 Testosterone to EP therapy Men
- CE 05 AR polymorphism
- Castration male breast ca
- Burger 07 TT to ET br protection M
- Bush 01 Wyeth sponsored HRT BCa
- Campagnoli 05 Pregnancy, progesterone, progestins BCa JSB&MB
- Campagnoli 05 Progesterone vs. progestins HRT BCa JSBMB
- Canada guidelines HRT SOGC BC
- Cancer 04 nurses health study HRT increase ER PR pos
- Cancer 10 Bresat Cancer Survivors in the US
- Carmona-Bayona AI Male BrCa
- Chemoprevention BCa with AI therapy 05
- Chen 04 Flaxseed plus TAM inh BCa Cell CCR
- Chen 06 Unopposed estrogen B Ca Risk AIM
- Chen 95 Life events Breast Cancer BMJ
- Chlebowski 03 E EP Risk br ca WHI JAMA
- Chlebowski 10 E plus progestin BCA JAMA
- Clark 83 PR prognosis BCa NEJM
- Clemons 01 Estrogen and risk Bca NEJM
- Cline von Schoultz Br density E vs EP AJOG
- Col 05 Meta HRT after BCa BCR
- Colditz 00 Nurses Health Study Increased Risk BCa AJE
- Colditz 05 E EP Br Ca CCR
- Colditz 92
- Colditz 93
- Colditz 95 NHS increased risk BCa E alone E&P NEJM
- Cole 69 Estrogen fractions BCa Lancet
- Collett ER PR AR survival
- Cooper 99 Luteal phase BCa timing C
- Copy of Head 98 Soy AMR
- Copy of Segaloff Test Therapy BC Cancer 51
- Cowan 81 Breast Cancer Incidence HO Prog Def JE
- Cummings 05 High Test risk Bca CEBP
- Dai 03 Urinary phytoestrogen BCa risk CEBP
- Danforth 10 Plasma androgen levels BCA IJC
- Dauvois Labrie 91 DHT inh BCa cell CR
- Davelaar 91 No increase BCa SC E2 Pellets Nederlands
- Davis 09 No increase BCa Testosterone therapy JSM
- de Gooyer 03 Tibol aromatase androgen Steroids
- Decker 02 ERT BC pts JNAMS
- DeLignieres 02 cohort TD oral prog vs. MPA Cl
- Dew 02 Tam receptors HRT BCa pts. Climacteric
- Dew 03 Vaginal estrogen therapy BC pts. Clim
- Dew 98 HRT in BCa pts. Cimacteric
- Dew Vaginal estrogen therapy BC pts. 03 Clim
- DeWatteville 60 Androgens Br Ca CO&G
- DHEA inhibits BC Role Androgens 03
- Dimitrakakis 02 ANdro and mam growth 02 F&S
- Dimitrakakis 03 T limits E stim breast Menopause
- Dimitrakakis 04 Br Ca Incidence TRT M
- Dimitrakakis 04 TRT decr BC risk JNAMS
- Dimitrakakis 06 ERa prol mam BCR
- Dimitrakakis 06 ER-alpha prolif BCR
- Dimitrakakis 09 Androgens and the Breast BMC
- Dimitrakakis C FARE2002 Winning Abstracts
- Dimitrakakis Glaser 10 Low Salivary T BCA BMC C
- Disaia 00 Editorial HRT BCa survivors AJOG
- DiSaia 96 HRT BCa survivors AJOG
- DiSaia 96 HRT in BCa survivors AJOG
- Doyen 10 AI therapy male BCa AO
- Duffy 04 Molecular markers endometrium ATAC AJOG
- Duffy 04 Molecular markers endometrium ATAC AJOG
- Dunnwald 07 ER PR BCa risk BCR
- Durna 02 HRT after BCa MJA
- Durna 04 BC pre men recurrence HRT Climacteric
- Durna HRT after BCa MJA 02
- Durnberger 78 T inh Br epithelium
- Eden, Progestins and BCa AJOG 02
- Eliassen NHS 08 2 OH 16 OH BCa risk CEBP
- Ellis 09 Low dose E2 met bca JAMA
- epidemiology of breast cancer bmj
- ES position statement androgens (BCa) 08
- Estriol BC Pratt 78 JCEM
- Estriol estrone Estradiol culture BC Lippman 77 CR
- Estriol safety no prolif Eu J. Ob
- Estrogen B Ca swings PDF
- Estrogen Metabolism a Complex Web JANA
- Fentiman 06 Male Br Ca Lancet
- Fentiman 06 Male Breast Cancer L
- Flaxseed
- Formby and Wiley 99 M&CB Prog BC
- Foss 56 Ca Breast Androgens Lancet
- Fournier 04 Br Ca Risk P vs P IJC
- Fournier 05 Breast Ca Risk P vs. P IJC
- Fournier 07 Prog vs progestins BCa BCRT
- Fournier 08 Progesterone vs. progestins BCRT
- Free T def women 04
- Friedman 07 Breast and Prostate Cancer model
- Friedman Breast Prostate Cancer Model BioMed
- Friedman Model ER BCA 09
- Fuqua 04 ERa ERb PgRA PgRB Br Ca BCRT
- Gambrell 83 Decreased B Ca EP HRT OG
- Gambrell 84 Hormones and cancer SMJ
- Gambrell Jr., Natrajan 06 Pellets T E cont rates Climacteric
- Gammon 91 PCO low risk br Ca AJE
- Geier 74 Uptake T in BCa vs Benign B EJE
- Geisler 07 Leptin BCa
- Gelfand 04 ed Dimit Add androgens to hrt Men
- Gelfand 04 ET to EPT M
- Giordano 02 BrCa in Men low T AIM
- Glaser 08 Vaginal HRT GOI
- Glaser Dim 11 Beneficial effects TE Maturitas
- GO 2006 Ovarian Ca BRCA Edi
- Goldenberg 73 Androgen therapy BCa JAMA
- gonzalez-Angulo 09 AR good prognosis BCA CCR
- Goodwin 01 Insulin Res and B Ca recurrence JCO
- Gotte_M
- Graham 97 Physioloical action of Progesterone EnRev
- Greendale 03 Br Density MPA Pr jnci
- Greendale 05 Endo hormones br density AJE
- Greendale 98 PEPI Sxs side effects OG
- Greendale 99 Mam density PEPI MP MPA AM
- Greendale 99 Prog increases Mam density AIM
- Greendale Br density MPA Pr jnci
- Gregoraszczuk 01 Pr induced secretion of GH, IGF… Br Ca Gyn Endo
- Guidozzi 99 ERT in BCa survivors IJG&O
- Guidozzi 99 ERT in Br Ca Survivors IJG&O
- HABITS editorial (good) Lancet 04
- HABITS Lancet 04 HRT BC pts
- HABITS reply Lancet 04
- Hackenberg 96 Andro inhibit BC cell lines JSBMB
- Hackenburg 88 DHT (high dose ER), Flutamide, CPA BC cells CR
- Haiman 02 BRCA I AR NHS CR
- Hankinson 98 No asso test fE2 BCa (NHS) JNCI
- Hasler 04 Safety of Soy
- Head 98 Soy AMR
- Heiman 43 Pr T inhibit mam prol CR
- Hemminki 11 Rates BCa Post men preventable BCRT
- HERS Trial Hulley 98 JAMA
- Highserum test BC JNCI 96
- Hofling 05 Tibolone Br Density Testosterone GE
- Hofling 06 Testosterone inhibits Br Prolif Men
- Holmberg 04 HABITS Lancet HRT BC pts
- Holmes, Aspirin Intake and Survival After Breast Cancer, 2010
- Hormone BC epid 05
- Hormone Research BMD ref 15
- Hornung 03 MT ME2
- HRT and increased br density but no Ca menomedsummer02
- HRT BC risk En related Ca 00
- HRT in BC pts. Men 05
- Hu 05 BRCA 1 aromatase Oncogene
- Hu 11 AR in BCa CCR
- Hulley 04 WHI Trial E2 alone JAMA
- Ingle 91 Tamoxifen vs tam plus androgen Cancer
- Intratumoral androgen BCa cells 10
- Iruela-Arispe 96 Progesterone inhibits angiogenesis JCI
- Isaksson 01 OCP BR prolif Free T low BCRT
- Ives 07 Editorial Preg after BCa BMJ
- Ives 07 Pregnancy after breast cancer BMJ
- Jama 46 Testosterone improves met br ca
- JAMA 60 Androgens and estrogens Rx
. Met B Ca
- Jama 64 nonprogression of disease testosterone derivitives
- JAMA 64 Testoserone Propionate 20%
- Jatoi 98 Timing Surg B Ca BCRT
- Jatoi 98 TIming Surg B Ca Survival BCRT
- Jordan 03 apototic action E2 BCa cells JNCI
- Jordan 05 E2 induced apotosis BCa cells JNCI
- Jordan Brodie Review AI BCa therapy
- Juricskay 97 Urinary serum T, DHEA BR Ca BCRT
- Kalish Barrett Connor Estradiol not Test IR
- Kandouz 99 Proapototic Androgen BCa cells SBMB
- Kenemans 09 Tibolone BCA LO
- Kennedy 64 Androgen therapy Leukmia Breast JAMA
- Kennedy, B. J., 53 brca and Androgens estrogens Rx JAMA
- Kesgegian 95 Mitotic fig and MIB 1 not Ki67 AJCP
- Key 02 Reanalyze endog hormone BCa risk JNCI
- Key 03 BMI Hormones BCa risk post JNCI
- Khera 09 Testosterone women SRM
- KI 67 not predictive Keshgegian 95 AJCP
- Kiecolt-Glaser 99 Stress Immune Cancer EJC
- Knight 05 Ovarian cysts decrease BCa IJC
- Kohama 97 DHEA T prevents DMBA BCa rats BCRT
- Kotsopoulos 06 HRT BRCA GO
- Kramer 06 T inh, E2, P, MPA BC cell lines EJOGRB
- Kuenen-Boumeester 96 AR Br Ca EJCa
- Kuhl 05 Pharm Estro Progest Climacteric
- Labrie 03 Androgens Inhibit BCa ER
- Labrie 93 Androgens Br Ca BCDP
- Lamar 58 p.10 Tpellet Rx Bca 750 mg JAMA
- Lamar 58 Testosterone Pellet Implants for Advanced Breast
- Lamar 58 Testosterone Pellet Implants for Advanced Breast
- Lange 08 Prog role BCa Steroids
- Lange 08 Prog role BCa Steroids
- Langer 90 AR Testos Prognosis Br Ca pts. ArGO
- Lapointe 99 Andro down reg bcl-2 Endo
- Laszlo 52 testosterone did not help bone mets JAMA
- Lawlor Hyperinsulinemia Breast Cancer Risk CC&C
- Le 06 Review Hormone imbalance BrCa paper
- Lee 99 Andro def incr pre men BC Clin Bio 99
- Lemon 80 Estriol Prvention Ca Acta Endo
- LHermite 08 TD P4 E2 Safety Maturitas
- Liao 02 Role of Androgens BCa Dose SB&MB
- Lillie 03 Test AR B Ca Risk Br Ca Research
- Lillie 03 Test levels BCa risk vs. AR BCR
- Limer 05 phytoestrogens protective BCR
- Lippert 03 Life Science Cell Culture Estriol stim
- Loeser 41 Testosterone implants Br Ca Lancet
- Loeser 48 Testosterone in Women OGS
- Loeser 54 Rx Met BCa androgen thyroid BMJ
- Longscope 03 Androgens Estrogens Br prol M
- Loss of PR in BC BCRT 02 Mote
- Lu 02 Cancer BCa Er Pr neg p53 pos aggressive
- Lu 02 Cancer BCa Er Pr neg p53 pos aggressive
- Lydon 00 Mammary Gland Progesterone action JMGBN
- Lyytinen 06 Vag E, po E3 no increase BCa vs. po TD E OG
- Macedo 06 Androgens Letrozole BCa MCF7 CR
- Mady 00Sex steroid in breast tissue DM
- Male Breast Cancer J Epi Bio 2005
- Malet 00 Pr E2 HBCa cells SBMB
- Marsden 00 Randomized trials HRT in BCa pts F&S
- Marsden 03 HRT BCa JSB&MB
- Marsden 06 HRT BCa survivors editorial Climacteric
- Marttunen 01 HRT Bca pts. Maturitas
- Marugo 92 DHT Flutamide AR BC cells JSBMB
- Maturita 05 Route Risk p vs p BC
- Mauvais-Jarvis 86 Antiestrogen action Progesterone BCRT
- McGuire 85 Role PR in Br Ca SemOnc
- McTiernan, Tw, Stanc 03 Adiposity, hormones BC JCO
- Messina 01 Soy BCa JN
- Meurer 02 HRT & Br Ca Recurrence and mortality JFP
- Micheli 04 Luteal insuf B Ca. IJC
- Million Women Study HRT and BC Lancet
- Missner 04 E, A, Pr B Ca risk JNCI
- Mohr 96 Serum Progesterone and BC BJCa
- Morch 09 HRT and Ovarian Ca JAMA
- Moskowitz 06 BHRT Safety Efficacy AMR
- Mousa AI to HRT br density no adverse bmd Menopause
- Mueller 08 Hormonal Ca in Cross sex EJE
- Munoz 98 AR neg male brCa worse JSBMB
- Nakata 03 Steroid sulfatase local E BC JSB&MB
- NAMS Pr vs progestin risk of breast cancer
- NAMS prog BC vs progestin
- Natrajan, Gambrell ERT in early BCa AJOG 02
- Natrajan, Gambrell ERT women BCa AJOG 99
- Ness 09 Methyl T increase BCa AIM
- Niewoehner 08 BCa gynecomastia men BMJ
- Norman 05 ed. HRT BC HRUpdate
- Nurses Study Chen 06 Unopposed Estrogen B Ca Arch IM
- Olsson 03 Cancer HRT progestins BC estriol inc
- Olsson Increase BC estriol Sweeden Cancer 03
- Onami 09 Male Breast Cancer
- Oomah 01 FLAXSEED Review
- Ortmann 02 Test 5 DHT inh BC lines GE
- Ozasa 89 DHEAS Cortisol Stress Gyn Pts GynOnc
- Page 99 Prognostic factors in BCa Concensus Statement
- Pandey 07 editorial TD testos Ca survivors
- Pant 08 Male Breast Ca MO
- Papa 90 Insulin Receptor Stim progestins,one CR
- Papa 96 Insulin Receptors BrCa JEI
- Park 00 BRCA I AR CR
- Parker 09 NHS Ovarian Conservation O&G
- Pasqualini 04 SERMs BC review BBActa
- Pearce 91 Hormones and Br Ca no dif EJC
- Persson 97 ET and EPT increase risk BCa IJC
- Peters 01 ERT fter BCa Ann Surg Onc
- Peters 09 AR inh ERa Prognostic CR
- Pg induced Growth factors in Br Ca
- Pichard 08 Insulin Resis BCA risk Mat
- Plu-Bureau 92 OCP BCa risk BJC
- Plu-Bureau 94 BJCa Progestogen BC risk
- Plu-Bureau 99 CD & P PC prog and BC risk
- Plu-Bureau Perc Prog BBD Fr Cohort 99 CDP
- Poujol 97 AR mutation Male BCa abstract
- Poulin 88 Androgens inhibit E induced proli BCRT
- Pr induced secretion of GH, IGF… Br Ca Gyn Endo
- Progestins and recurrent breast Ca 05 Chleb
- Pujol 01 Timing Surg B Ca Survival Cancer
- Purohit 02 Role of cytokines Est syn, B Ca BCR
- Rayson 98 Receptors male BCa wrong conclusion Cancer
- Rebbeck 99 AR CAG BRCA1 AJHG
- Recchione Secreto 95 E2, T DHT Br Ca tissue JSBMB
- Reed Purohit 97 BCa Cytokines Estrogen Syn ER
- Reid 96 Endocrine paracrine Br Ca BJS
- Reid Endocrine Paracrine Br Ca Annals
- Riley 81 Stress immune response Neoplasia Sci
- Riley 81 Stress Immune sys Neoplasia Science
- Rochefort 79 Pharm doses Androgen ER uterus
- Rochefort 79 Pharm doses Androgen ER uterus RS
- Rogan 06 I3C DIM Review iv
- Rookus 94 OCP increases B Ca Risk Lancet
- Rosal 11 ER PR Tam Treated Br tissue BCRT
- Rosenberg 06 No increase BCa vag estrogen BCR
- Rossouw 02 WHI E EP BrCa risk JAMA
- Russo 99 ER PR Breast proliferation BCRT
- Schairer 00 E EP BCa risk NCI BCDDP JAMA
- Schneider 09 Hormone Levels BCA Mat 09
- Schover 08 TRT risky Bca see Guay and Traish reply FS
- Schumacher 07 Progesterone in HRT Endo Rev
- Secreto 91 serum and urinary androgens risk of BCa CR
- Seeger 08 Progestins BCa vitro vivo SBMB
- Segaloff 75 Hormonal therapy of breast cancer CTR
- Segaloff Hormones in Cancer Therapy 51 NOMSJ
- Segaloff Test Therapy BC Cancer 51
- Senie 91 Timing Surg B Ca survival AIM
- Sephton 00 Diurnal cortisol survival BCa JNCI
- Setiawan Stanczyk 06 Racial differences hormones BCa CEBP
- Shibuya 08 Intrtumoral sex steroids BCA ERC
- Shilkaitis 05 DHEA decreases BCa BCR
- Shin 03 BRCA 2 AR PNAS
- Shyamala 99 Progesterone differentiation Mammary gland JMGB&N
- Sieri 04 ORDET diet trial CEBP
- Sieri 09 T levels BCA CEBP
- Sikora 09 Androgens stim BCA ER DOSE BCRT
- Simpson 03 Sources of Estrogen JSBMB
- Simpson Davis 00 Local Estrogen Production TEM
- Simpson Davis 01 Aromatase Review E
- Slagter 06 androgen effect br tissue JH&C
- Soderqvist 97 Breast prolif luteal AJOG
- SOGC 05 Abortion Br Ca
- SOGC Pregnancy Br Ca 02
- Som Davis Test Therapy and Br Ca Risk Mat 04
- Somboonporn Davis 04 Test BCa ER
- Somboonporn Davis 04 Testosterone Effect Breast ER
- Sonne-Hansen 04 Aromatization T stim MCR-7 JSB&M
- Sovak 97 NF expression Pathogenesis BCa JCI
- Stanczyk 07 Standardization hormone assay CEBP
- STEROIDSTOFFWECHSEL BEI BRUSTKREBS. II. 1958 Schubert
- Stockholm HRT BCa von Schoultz NCI 05
- Stolfi 80 combined T 5FU brca CR
- Sturgeon 04 No asso E2 T premen B Ca vs. P CC&C
- Suzuki 01 5a reductase BCa JCEM
- Szymczak 98 Sex steroids fatty tissue SA
- Szymczak steroids in fat and breast tissue Steroids
- Tally 73 Androgen therapy BCa Cancer
- Tamimi 06 Methyltest breast ca Archives IM
- Test and Br Ca FS 02
- Test and Br Ca Risk C E B 05
- Test and Br Ca Risk Mat 04
- Test Effects on Breast Som 04
- Test inhi E stim Br Dimitrakakis JNAMS 03
- Testosterone Monograph
- Testosterone Propionate 20% JAMA
- Teststosterone Deficiency Women 2004
- Thomas 92 BCa Males low T AJE
- Thomas 92 BCa Men low T AJE
- Thomas 92 Low T Increase BCa risk men AJE
- Thomas 97 BrCa Men Risk factor low T abstr
- Thomas 97 hormone levels BCa risk BJC
- Thompson 05 Flaxseed Br Ca CCR
- Thompson 58 ref to Adair TT CaB JAMA
- Timing no PR yes survival BC Pujol 01 Cancer
- Timing surgery BC Prognosis Jatoi 98 BCRT
- Tormey 79 Increased bm support during CTX with THT ASCO
- Tourmey 83 Tam plus Androgen Met Br Ca AIM
- Traish 08 editorial replay Schover_Leslie_R
- Traish 10 T and BCa HMBCI
- Tutera Reduction Br Ca pellets E2 T
- Ursin 97 E2 E1 Urine not 2 OH Br ca. EHP
- Vaginal estrogen therapy BC pts. Dew 03 Clim
- Vassilopoulou-Sellin 02 ERT in BrCa sruvivors Cancer
- Vassilopoulou-Sellin 94 HRT BCa JNCI abstract
- Vassilopoulou-Sellin 97 GOnc ERT BC
- Vassilopoulou-Sellin JCO 99 ERT BCa
- Veronesi 94 TIming Surg BCa survival Lancet
- Veronesi 98 Tam HRT Br Ca Lancet
- von Schoultz 05 Stockholm HRT BCa NCI
- von Schoultz 89 Progestogen neg mood, Mat
- Von Schoultz 96 Hormonal Reg Br M
- von_Schoultz 07 Androgens and the Breast Mat
- Vooijs 95 Safety intravag estriol OG
- Wang 66 Serum T Br Ca EJC
- Warner 89 T inh perinatal lob CR
- Wedren AR Vit D R post men BCa CEBP
- Weiderpass 99 Oral not Vaginal E3 increases endo Ca Lancet
- Weiss 05 Male Br Ca CEBP
- WHI JAMA Estrogen plus progestin
- WHI Estrogen alone CEE Br Ca 06
- WHI Trial 2002 JAMA
- Wiebe 06 Prog metabolites BCa ERC
- Wild 00 PCOS no inc CHD despite risk factors CE
- Wile 89 Hormones and Br Ca AJS
- Wile 93 HRT in Treated B Ca Pts. AJS
- Wile 95 HRT BrCa pts. Mat
- Wood 07 Vagianal Prog BrCa monkey Men copy
- Wood 09 Mammary and Endo effect T therapy Menopause
- Woolcott Stanczyk 10 Hormone conc BCa risk E-RC
- Wysowski 84 Hormone levels Br Ca no dif AJE
- Yaghjyan 11 Local estrogens breast tissue CCC
- Yamaguchi 05 Tumor stromal E Br Ca CR
- Yared 02 Effects of estrogens on breast cells
- Yeh 00 BRCA 1 AR Apotosis PNASusa
- Zava 77 ER in Testosterone induced Regression BCa CR
- Zava 78 Androgen action ER Endo
- Zava 78 Androgen action through ER Endo
- Zava 78 Br Ca Androgens ER pharmac dose Sci
- Zava 97 Estrogenic activity BCa cell culture EHP
- Zava 97 Estrogenic activity BCa cell culture EHP.htm
- Zeleniuch-Jacquotte 97 E2 not T Bca risk AJE
- Zhou 00 Testosterone inh MEP FASEB
- Zhou 00 Testosterone inhibits MEP FASEB
- Zumoff 82 Prog hypothesis BCa CR
- Zumoff 95 Test levels pre-men JCEM
- Zhu 98estrogen metabolism in target cells Carc
- Yu 11 AR Bca Pg AO.pdf
- Park 10 AR lower tumor burden target Triple neg AO.pdf
- Asano 03 TE upregulated ER B EJ.pdf
- Nahleh 10 AR as target for ER neg BCa Future oncology..pdf
- Adelson 11 Hormonal modulation BCa Clinics.pdf
- Dimitrakakis 11 Androgens and BCa men and women Clinics.pdf